Australian Securities Exchange

CanAlaska Deals Three Uranium Projects in the Athabasca Basin

Thursday, September 23, 2021 - 1:30pm

Vancouver, British Columbia--(Newsfile Corp. - September 23, 2021) - CanAlaska Uranium Ltd. (TSXV: CVV) (OTCQB: CVVUF) (FSE: DH7N) ("CanAlaska" or the "Company") is pleased to announce it has entered into a Letter of Intent ("LOI") with Terra Uranium Pty Ltd ("Terra"), an Australian private limited corporation, to allow Terra to earn up to an 80% interest in CanAlaska's 100%-owned Waterbury East and McTavish projects, and up to a 20% interest in CanAlaska's 100%-owned Waterbury South project. These projects total 5,010 hectares in the Eastern Athabasca Basin in Saskatchewan, Canada (the "Projects") (Figure 1).

Key Points: 
  • These projects total 5,010 hectares in the Eastern Athabasca Basin in Saskatchewan, Canada (the "Projects") (Figure 1).
  • Terra may earn up to an 80% interest in each of the Waterbury East and McTavish projects by undertaking work and payments in three defined earn-in stages on each project (tables 1 and 2).
  • Cumulatively, Terra may earn an additional 20% interest ("60% Option") in the projects by paying a further A$400,000 and incur A$5,000,000 in exploration expenditures within 18 months of ASX approval date.
  • CanAlaska will be operator of the projects through the 60% Option threshold and charge a 20% operator fee to Terra.

International Lithium Corp. to Dispose of Its Stake in Mariana to Ganfeng for CAD$ 16.8m

Tuesday, September 21, 2021 - 1:30pm

Clearly as the 91.4% owner already, Ganfeng was the most logical buyer provided that the price was right.

Key Points: 
  • Clearly as the 91.4% owner already, Ganfeng was the most logical buyer provided that the price was right.
  • The Company also has a joint venture with Ganfeng in Ireland (the Avalonia project), and this is governed by another 2014 agreement between the Company and Ganfeng.
  • In that agreement Ganfeng may increase its shareholding in Blackstairs from 55% to 79% if it spends CAD$ 10m on exploration before September 2022.
  • In addition to exploration expenditure, the Company plans to repay most of its existing debt following this transaction for Mariana.

Elixinol Expands Product Line With First CBD Pet Collection

Wednesday, September 22, 2021 - 2:12pm

WESTMINSTER, Colo., Sept. 22, 2021 /PRNewswire/ -- Elixinol , a global hemp-derived CBD brand and industry veteran, introduced its first line of pet products.The new collection is specifically formulated for dogs and includes a bacon-flavored tincture and two functionally focused CBD dog chews targeting specific benefits.

Key Points: 
  • WESTMINSTER, Colo., Sept. 22, 2021 /PRNewswire/ -- Elixinol , a global hemp-derived CBD brand and industry veteran, introduced its first line of pet products.The new collection is specifically formulated for dogs and includes a bacon-flavored tincture and two functionally focused CBD dog chews targeting specific benefits.
  • Elixinol Pet products go through the same rigorous third-party testing and quality control as the brand's full product line.
  • The Elixinol Pet collection includes:
    CBD works with your furry friend's endocannabinoid system to support daily wellness.
  • Elixinol is an original pioneer in the CBD industry founded in 2014 with the mission to bring CBD into the forefront to help people unlock their full potential.

Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021

Tuesday, September 21, 2021 - 1:38pm

The final OS data will be presented by Immutep at SITC 2021 as a late breaker poster presentation.

Key Points: 
  • The final OS data will be presented by Immutep at SITC 2021 as a late breaker poster presentation.
  • Interim OS data from the trial was presented in a spotlight presentation at the San Antonio Breast Cancer Symposium in December 2020.
  • Immutep will make the poster available on its website following publication at SITC 2021 and will host a webinar for investors after the conference.
  • SITC is the worlds leading member-driven organisation specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

Second Industry Body Updates Guidance for Use of PSMA PET Imaging

Tuesday, September 21, 2021 - 1:31am

It follows updated guidance from the National Comprehensive Cancer Network (NCCN)1, which recognises the increased sensitivity and specificity of PSMA PET tracers, compared to conventional imaging for detecting micrometastatic disease, at both initial staging and biochemical recurrence.

Key Points: 
  • It follows updated guidance from the National Comprehensive Cancer Network (NCCN)1, which recognises the increased sensitivity and specificity of PSMA PET tracers, compared to conventional imaging for detecting micrometastatic disease, at both initial staging and biochemical recurrence.
  • The systematic review2 also noted:
    PSMA PET may have additional use in selecting patients for PSMA directed therapy and assessing response to therapies.
  • PSMA PET radiotracers, similar to other radiopharmaceuticals, have an excellent safety profile, given the sub-pharmacological mass dose and high specific activity administered.
  • Access to PSMA PET will be widely available and this game-changer technology will ultimately become part of the routine staging of prostate cancer patients.

Sims Limited Introduces Women Leading @ Sims

Thursday, September 16, 2021 - 11:00am

NEW YORK, Sept. 16, 2021 /PRNewswire/ -- Sims Limited , a global leader in metal recycling and data center IT circularity, and an emerging leader in municipal recycling and renewable energy, announces the launch of the Women Leading @ Sims, a program designed to support and develop female leaders within the company.

Key Points: 
  • NEW YORK, Sept. 16, 2021 /PRNewswire/ -- Sims Limited , a global leader in metal recycling and data center IT circularity, and an emerging leader in municipal recycling and renewable energy, announces the launch of the Women Leading @ Sims, a program designed to support and develop female leaders within the company.
  • Women Leading @ Sims provides the internal mentorship and skills needed for career growth that women requested, and it is packaged in a virtual, monthly workshop-style course.
  • "Women Leading @ Sims is a new and exciting opportunity for us to recognize and support the leadership capabilities of high performing women at Sims, and I am honored to be the co-creator and executive sponsor of this initiative," stated Ingrid Sinclair, global president of Sims Lifecycle Services.
  • There is a plethora of research that indicates women have unique learning and development needs, and Women Leading @ Sims was designed with those needs in mind," said Brad Baker, group chief human resources officer for Sims Limited.

Online Brokerage Tiger Brokers Announces Q2 2021 Results; Singapore's Generation Z New Account Openings Increased By Over 90% Y/Y

Wednesday, September 15, 2021 - 2:00am

Eng Thiam Choon, Chief Executive Officer, Tiger Brokers (Singapore), said, "Generation Z, or the internet generation, can be regarded as one of the most disruptive generations ever.

Key Points: 
  • Eng Thiam Choon, Chief Executive Officer, Tiger Brokers (Singapore), said, "Generation Z, or the internet generation, can be regarded as one of the most disruptive generations ever.
  • "At Tiger Brokers, we are constantly working to introduce relevant financial products, services and activities to keep the different types of investors engaged.
  • About Tiger Brokers (Singapore) Pte Ltd.
    Tiger Brokers (Singapore) Pte Ltd ("Tiger Brokers (Singapore)") is a brokerage firm operating with a Capital Markets Services (CMS) Licence from the Monetary Authority of Singapore (MAS).
  • Tiger Brokers (Singapore) is the Singapore entity of UP Fintech Holding Limited (NASDAQ: TIGR), known as "Tiger Brokers" in Asia, a leading online brokerage firm focusing on global investors.

NCCN Guidelines Updated to Include PSMA-PET Imaging

Tuesday, September 14, 2021 - 1:36am

The NCCN Guidelines are a recognised standard for clinical direction and policy in cancer care and are used widely by clinicians and payors.

Key Points: 
  • The NCCN Guidelines are a recognised standard for clinical direction and policy in cancer care and are used widely by clinicians and payors.
  • The updated guidelines state that the NCCN Panel does not feel that conventional imaging is a necessary prerequisite to PSMA-PET and that PSMA-PET/CT or PSMA-PET/MRI can serve as equally effective, if not more effective front-line imaging tools for these patients.
  • The updated guidelines now include Ga-68 PSMA-11 PET/CT to be considered as an alternative to standard imaging of bone and soft tissue.
  • The inclusion of PSMA-PET imaging, including with Ga-68, the isotope used in our investigational imaging product Illuccix further signals the emergence of PSMA-PET imaging as a state-of-the-art imaging modality.

FDA Approves Phase II Kidney Cancer Therapy Study

Monday, September 13, 2021 - 11:41pm

MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) to undertake a clinical study of the Companys investigational kidney cancer therapy, TLX250 (177Lu-DOTA-girentuximab).

Key Points: 
  • MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) to undertake a clinical study of the Companys investigational kidney cancer therapy, TLX250 (177Lu-DOTA-girentuximab).
  • The STARLITE 2 study is a single arm, investigator-led Phase II study in patients with advanced clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer.
  • This therapy, along with patient selection and treatment response assessment with our CA9-targeting imaging agent TLX250-CDx may potentially offer a new paradigm of more accurate staging and personalised treatment for kidney cancer patients through a theranostic approach.
  • Telixs companion investigational diagnostic imaging agent TLX250-CDx (89Zr-DFO-girentuximab) is currently the subject of a global Phase III trial (ZIRCON trial, NCT03849118).

Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging

Sunday, September 12, 2021 - 11:36pm

(Radius) for Telixs prostate cancer investigational imaging product Illuccix (Kit for the preparation of 68Ga-PSMA-11 injection) for the Italian market.

Key Points: 
  • (Radius) for Telixs prostate cancer investigational imaging product Illuccix (Kit for the preparation of 68Ga-PSMA-11 injection) for the Italian market.
  • This agreement builds on the support Radius has provided Telix in distributing 68Ga-PSMA-11 for magisterial use in Italy.
  • Radius CEO, Dr. Mauro Mei stated, This commercial partnership with Telix will enable us to open the door to state-of-the-art PSMA imaging for the 39,000 men diagnosed with prostate cancer each year in Italy.
  • Italy is an important market and we look forward to working with Radius to bring this highly anticipated imaging agent to Italian men, living with prostate cancer, once regulatory approval is received.